TY - PAT
T1 - Immunosuppressive glycoforms of soluble CD52
AU - Harrison, Leonard Charles
AU - Bandala-Sanchez, Esther
AU - Goddard-Borger, Ethan David
AU - Packer, Nicolle Hannah
AU - Mansour, Shathili Abdulrahman
N1 - Designated States:
AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
PY - 2022/1/12
Y1 - 2022/1/12
N2 - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.
AB - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.
M3 - Patent
M1 - EP3935073
ER -